VERTEX PHARMACEUTICALS INC MA（VRTX）の決算・業績分析
VERTEX PHARMACEUTICALS INC MAの2025年有価証券報告書をAI分析。売上高$12.0B(+8.9%)。営業利益$4.2B。Health Care。
目次
VERTEX PHARMACEUTICALS INC MAの2025年度 業績サマリー
VERTEX PHARMACEUTICALS INC MA（証券コード: VRTX）の2025年度決算・業績分析。売上高は$12.0B（前年比+8.9%）。営業利益は$4.2B（前年比+1891.9%）。純利益は$4.0B（前年比+838.1%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
VERTEX PHARMACEUTICALS INC MAの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- VRTX achieved $8.9B revenue in FY2024 (+17.9% YoY) with operating income of $4.3B (+54.8% YoY) (XBRL).
- Strong profitability with 48.2% operating margin and 37.2% net margin (XBRL), supported by $4.5B EBITDA (49.9% of revenue).
- Robust cash position of $6.8B (XBRL) and 32.9% ROE (XBRL) reflect disciplined capital management.
- R&D investment of $2.5B (XBRL) underscores focus on innovation, with CASGEVY as a key growth driver.
VERTEX PHARMACEUTICALS INC MAの売上高変化の要因
- •VRTX generated $8.9B revenue in FY2024, reflecting a 26.5% CAGR over five years (XBRL). Growth drivers include the commercial success of CF treatments (e.g., TRIKAFTA) and the launch of CASGEVY, which is critical for future growth (10-K). Historical time series data shows revenue increasing from $3.0B in FY2020 to $8.9B in FY2024, with projections of $9.9B in FY2025 (XBRL).
VERTEX PHARMACEUTICALS INC MAの営業利益変化の要因
- •Profitability metrics show a 48.2% operating margin (up from 37.2% in FY2023) and 37.2% net margin (up from 30.6% in FY2023) (XBRL). Operating income surged to $4.3B (+54.8% YoY) and EBITDA reached $4.5B (49.9% of revenue). Cost efficiency is evident in the 2.3% CapEx intensity (XBRL).
VERTEX PHARMACEUTICALS INC MAの事業リスクと対応
Inability to develop or commercialize new products could harm the business (10-K).
Failure to sustain CF medicine revenues would reduce stock price (10-K).
Commercialization of CASGEVY is critical for growth (10-K).
Competitors with superior products could reduce revenues (10-K).
Safety issues or regulatory non-compliance could lead to product approval loss (10-K).
Regulatory risks include non-compliance with health care laws and extended approval timelines for cell/gene therapies (10-K).
VERTEX PHARMACEUTICALS INC MAの今後の見通し・業績予想
VERTEX PHARMACEUTICALS INC MAの事業内容
Vertex Pharmaceuticals is a global biotechnology company focused on developing transformative medicines for serious diseases, primarily in specialty markets (10-K). Key products include five cystic fibrosis (CF) medicines (e.g., TRIKAFTA, ALYFTREK), CASGEVY (a gene-edited therapy for sickle cell disease and transfusion-dependent beta thalassemia), and JOURNAVX (pain management). The company's competitive advantages include a robust R&D pipeline (e.g., VX-522 with Moderna), proprietary technologies like CRISPR/Cas9 (CASGEVY), and leadership in CF treatments (covering ~75% of U.S./EU CF patients) (10-K). No significant customer concentration is reported (N/A).
VERTEX PHARMACEUTICALS INC MAのAI業績分析レポート（2024年度）
Vertex Pharmaceuticals Inc. (VRTX) FY2024 Annual Report Analysis
Highlights
Business Overview
Vertex Pharmaceuticals is a global biotechnology company focused on developing transformative medicines for serious diseases, primarily in specialty markets (10-K). Key products include five CF medicines (e.g., TRIKAFTA, ALYFTREK), CASGEVY (gene-edited therapy for SCD/TDT), and JOURNAVX (pain management). The company's competitive advantages include a robust R&D pipeline, proprietary technologies like CRISPR/Cas9, and leadership in CF treatments (covering ~75% of U.S./EU CF patients) (10-K). No significant customer concentration is reported (N/A).
Revenue Analysis
VRTX achieved $8.9B revenue in FY2024, reflecting a 26.5% CAGR over five years (XBRL). Growth is driven by the commercial success of CF treatments and the launch of CASGEVY. Historical time series data shows revenue increasing from $3.0B in FY2020 to $8.9B in FY2024, with projections of $9.9B in FY2025 (XBRL).
Profitability Analysis
Profitability metrics show a 48.2% operating margin (up from 37.2% in FY2023) and 37.2% net margin (up from 30.6% in FY2023) (XBRL). Operating income surged to $4.3B (+54.8% YoY) and EBITDA reached $4.5B (49.9% of revenue). Cost efficiency is evident in the 2.3% CapEx intensity (XBRL).
Balance Sheet Analysis
VRTX maintains a strong balance sheet with $6.8B cash (XBRL), 44.4% equity ratio, and 0.51x debt-to-equity ratio (XBRL). Liquidity is robust, with a current ratio of 3.99x (XBRL). Total assets grew to $22.7B in FY2024, while total equity increased to $10.1B (XBRL). ROE of 32.9% and ROA of 14.6% highlight effective capital utilization (XBRL).
Cash Flow Analysis
Operating cash flow reached $4.1B (XBRL), with free cash flow of $3.9B after $205M in CapEx (XBRL). Investing cash flow was -$321M (XBRL), primarily due to capital expenditures. Financing cash flow was -$68M (XBRL), with no share repurchases reported (XBRL).
Working Capital Analysis
Working capital efficiency metrics include a 190-day cash conversion cycle (CCC), with 64 days receivables, 250 days inventory, and 123 days payables (XBRL).
Risks
Outlook
No specific management guidance is provided in the 10-K, but historical trends suggest continued growth in revenue and profitability. The company's focus on innovation and commercialization of CASGEVY is expected to drive future performance (XBRL).
Historical Time Series
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | 3.0B | 4.2B | 6.2B | 7.6B | 8.9B | 9.9B |
| Operating Income | 635M | 1.2B | 2.9B | 2.8B | 4.3B | 3.8B |
| Net Income | 2.1B | 1.2B | 2.7B | 2.3B | 3.3B | 3.6B |
| Total Assets | 8.3B | 11.8B | 13.4B | 18.2B | 22.7B | 22.5B |
| Total Equity | 2.0B | 4.4B | 6.1B | 8.7B | 10.1B | 13.9B |
| Operating Cash Flow | 1.3B | 1.6B | 3.3B | 2.6B | 4.1B | 3.5B |
Health Careの企業一覧
VERTEX PHARMACEUTICALS INC MAと同じ「Health Care」セクターの企業